Tympanic paraganglioma

Summary

Tympanic paraganglioma (MONDO:0023682) is a disease. A subtype of head and neck paraganglioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tympanic paraganglioma
Mondo ID	MONDO:0023682
MeSH	D043604
NCIT	C8428
SNOMED CT	253031000
UMLS	C0474820
MedGen	105375
GARD	0008658
Anatomy (UBERON)	UBERON:0004114
Is cancer (heuristic)	no

Also known as: Glomus tympanicum paraganglioma · Glomus Tympanicum Tumor · Glomus tympanicum tumor · Glomus Tympanicum Tumors · Glomus Tympanicum Tumour · Glomus tympanicum tumour · Glomus Tympanicum Tumours · Tumor, Glomus Tympanicum · Tumors, Glomus Tympanicum · tympanic paraganglioma

Disease family

This is a subtype of head and neck paraganglioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic nervous system neoplasm › paraganglioma › head and neck paraganglioma › tympanic paraganglioma

Related subtypes (3): carotid body paraganglioma, jugulotympanic paraganglioma, vagus nerve paraganglioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.